Tesla makes the news with its all-time high and rising, up to its inclusion in the S&P500 by mid-December. But, over the last month, its arch adversary, Oils, has managed a…

It immediately appeared that the BioNTech(licensed by Pfizer) vaccine news of last week would trigger a logistics challenge of gargantuan proportions. As a reminder, usual drug distribution mechanisms are not…

BCP has been one the worst performers among our banks’ universe year-to-date. At -60%, the stock has managed to double the sector’s correction. This could sound strange at first sight…

As part of an indiscriminate sell-off, CaixaBank’s share price moved in tandem with the rest of the sector until the summer, when it started to overperform (+7% ytd) ahead of the…

The mood music stopped about six months ago on a pre-COVID-19 high (19/02). It pays to group stocks into: a) those which, six months later, outperform their pre-COVID-19 highs, and…

With central banks’ liquidity guns in action over the last three months, it is worth checking the successful long-short trades. This is obviously ex post work but it may give an extra…

AlphaValue’s Buy & Hold Portfolio continues to surprise on the positive side. The ytd outperformance is 15% so that it is down only 2% in absolute terms. Over the last…

AlphaValue has maintained over the last 6 years a Buy & Hold list of 25 names which has consistently outperformed. There is hardly ever any change to that list as a quality…

We still hold the view that a second leg of price correction is likely, now that the extent of stimuli across the world is known/discounted while investors understand somewhat better…

When we last teased about Sonova in September 2018, the world’s No.1 hearing aids manufacturer’s first generation Made-for-All/MFA product (offers iPhone and Android connectivity) was struggling to find traction. If…